Caution Concerning Forward-Looking Statements

This website may contain information considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflects management's expectations. Any statements that express or involve discussions with respect to predictions, expectations, estimates, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements.” We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: the extent and duration of the COVID-19 pandemic, economic conditions, potential issues related to financial situation, competition, the ability to retain key personnel, product acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, suppliers and employees, inability to expand sales and channels, legislation or regulations affecting product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, litigation and investigations, and other known and unknown risks and uncertainties. You are cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s most recently filed Annual Reports on Form 10-K and in Gilead’s Quarterly Reports on Form 10-Q, all of which are on file with the U.S. Securities and Exchange Commission (SEC) and available on this website under https://investors.gilead.com/financial-information/sec-filings.

No Duty to Update

Gilead press releases, investor presentations and other materials on this website are archived on this website for historical purposes only. Information contained in these materials or otherwise included on this website is based on information available to us and is current at the time of publication. This information may change over time and may or may not be accurate after the time of publication. Gilead has no intention and specifically disclaims any duty to update the information in these historical materials. Investors should not rely upon the information as current or accurate after the time of publication.

Clinical Development Pipeline

The information included on this website reflects Gilead’s clinical development pipeline and is not intended for promotional purposes. It includes both new product candidates as well as select new indications of currently approved products that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline candidates to be discontinued or delayed, or to fail to reach the market. There can be no guarantee that pipeline candidates will receive regulatory approval or that they will prove to be commercially successful.

Non-GAAP Financial Measures

This website may contain certain non-GAAP financial measures, adjusted to include or exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular period are available in Gilead’s earnings materials for the related period.

ESG Information

This website contains information about Gilead’s environmental, social and governance (ESG) initiatives, goals and progress. Our ESG goals are aspirational and may change. Statements regarding these goals or expectations regarding our progress on these goals are not guarantees or promises that they will be met. ESG information may be based on standards for measuring progress that are still developing, controls and processes that continue to evolve, and assumptions that are subject to change in the future. ESG information may not be considered material for SEC reporting purposes. In the context of the ESG information included on this website, the term “material” is distinct from, and should not be confused with, such term as defined for SEC reporting purposes.

Third-Party Websites

Third-party hyperlinks throughout this website are provided for convenience only, and the content on the referenced third-party websites is not incorporated by reference into this website, nor does it constitute a part of this website. Gilead assumes no liability for the content contained on the referenced third-party websites.

Disclosure Channels

Investors and others should note that in addition to this website, SEC filings, press releases, public conference calls and webcasts, we also use other corporate channels as a means of disclosing information about Gilead and for complying with our disclosure obligations under Regulation FD. The information that we post through these channels may be deemed material. This list may be updated from time to time.

https://twitter.com/GileadSciences https://twitter.com/kitepharma https://www.linkedin.com/company/gilead-sciences https://www.linkedin.com/company/kite-pharma-inc https://www.instagram.com/GileadSciences